KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash & Equivalents (2016 - 2025)

CRISPR Therapeutics AG's Cash & Equivalents history spans 11 years, with the latest figure at $347.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 16.51% year-over-year to $347.6 million; the TTM value through Dec 2025 reached $347.6 million, up 16.51%, while the annual FY2025 figure was $347.6 million, 16.51% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $347.6 million at CRISPR Therapeutics AG, up from $286.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.6 billion in Q2 2021 and bottomed at $193.6 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $464.6 million (2023), against an average of $554.0 million.
  • The largest annual shift saw Cash & Equivalents tumbled 77.04% in 2022 before it surged 105.4% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $923.0 million in 2021, then plummeted by 77.04% to $211.9 million in 2022, then skyrocketed by 83.82% to $389.5 million in 2023, then decreased by 23.41% to $298.3 million in 2024, then rose by 16.51% to $347.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Cash & Equivalents are $347.6 million (Q4 2025), $286.5 million (Q3 2025), and $193.6 million (Q2 2025).